Roche moves to broaden Kadcyla use in biosimilar defense

Roche aims to broaden use of its Kadcyla breast cancer drug as the Swiss pharmaceuticals giant defends itself against rivals who are crowding in with cheaper biosimilar copies of its older, patent-expired mainstay Herceptin.

from Reuters: Health https://reut.rs/2TtffSt
via IFTTT

• Tweet
• Share
• Share
• Share
• Share